TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02264613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALRN-6924
Description: ALRN-6924 will be administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALRN-6924
Description: ALRN-6924 will be administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALRN-6924
Description: ALRN-6924 will be administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALRN-6924
Description: ALRN-6924 will be administered as an IV infusion
Study: NCT00361465

Intervention type: OTHER
Intervention: EMG and Kinematics recording
Description: The experimental protocol envisages the recording of the movement and the bilateral recording of activity EMG during three types of tasks:~discrete driving tasks: movements of inflection and extension of the wrist car-generated, or produced in answer to an imperative stimulus try driving repetitive: sequence of inflection-extension of the wrist unilateral, bilateral in phase and bilateral in opposition of phase.~try driving complexes: movement of inflection and extension of the wrist with concurrent realization of a driving task controlatérale different, or of a cognitive task.~For the Parkinsonian patients, these various tests will be carried out twice: without antiparkinsonian treatment (off) and under treatment (one).

Intervention type: OTHER
Intervention: EMG and Kinematics recording
Description: The experimental protocol envisages the recording of the movement and the bilateral recording of activity EMG during three types of tasks:~discrete driving tasks: movements of inflection and extension of the wrist car-generated, or produced in answer to an imperative stimulus try driving repetitive: sequence of inflection-extension of the wrist unilateral, bilateral in phase and bilateral in opposition of phase.~try driving complexes: movement of inflection and extension of the wrist with concurrent realization of a driving task controlatérale different, or of a cognitive task.~For the Parkinsonian patients, these various tests will be carried out twice: without antiparkinsonian treatment (off) and under treatment (one).

Intervention type: OTHER
Intervention: EMG and Kinematics recording
Description: The experimental protocol envisages the recording of the movement and the bilateral recording of activity EMG during three types of tasks:~discrete driving tasks: movements of inflection and extension of the wrist car-generated, or produced in answer to an imperative stimulus try driving repetitive: sequence of inflection-extension of the wrist unilateral, bilateral in phase and bilateral in opposition of phase.~try driving complexes: movement of inflection and extension of the wrist with concurrent realization of a driving task controlatérale different, or of a cognitive task.~For the Parkinsonian patients, these various tests will be carried out twice: without antiparkinsonian treatment (off) and under treatment (one).
Study: NCT03533660

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Feedback
Description: Participant will receive a brief feedback on alcohol use data downloaded from the ABM and information about treatment resources

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: Participant will receive information on self reported alcohol use and information about remaining abstinent and about treatment resources
Study: NCT02032576

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECT for depressed patients
Description: electroconvulsive therapy with a bipolar brief pulse square wave
Study: NCT01723969

Intervention type: GENETIC
Intervention: Tumour markers testing
Description: Tumour markers testing in patients advanced or metastatic colo-rectal cancer.
Study: NCT01471821

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: antiretroviral treatment
Description: antiretroviral treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antiretroviral treatment
Description: antiretroviral treatment
Study: NCT02905578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administered intravenously the same day as nab-paclitaxel and ascorbate Administered after nab-paclitaxel and before ascorbate~* given for 3 weeks out of the 4 week cycle~* standard dose reductions are used~* up to 2 cycles are administered before standard of care CT scan~* decision to continue therapy is based disease response to therapy as measured from the CT scan~* treatment continues until disease progression is identified
Study: NCT04088331

Intervention type: DEVICE
Intervention: AMS 800 Artificial Urinary Sphincter
Description: The AMS 800 Artificial Urinary Sphincter (AUS) is an implantable, fluid filled, solid silicone elastomer device used to treat stress urinary incontinence due to reduced urethral/bladder outlet resistance (intrinsic sphincter deficiency). It is designed to restore the natural process of urinary control. The device simulates normal sphincter function by opening and closing the urethra under the control of the patient.
Study: NCT02905578

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Administered intravenously the same day as nab-paclitaxel and ascorbate Administered after nab-paclitaxel and before ascorbate~* given for 3 weeks out of the 4 week cycle~* standard dose reductions are used~* up to 2 cycles are administered before standard of care CT scan~* decision to continue therapy is based disease response to therapy as measured from the CT scan~* treatment continues until disease progression is identified
Study: NCT00783172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000mg/m2, IV (in the vein) over 30 minutes after treatment with OGF; first cycle is consecutive seven weeks and one week off; subsequent cycles are three weeks on and one week off.
Study: NCT02905578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: Administered intravenously the same day as nab-paclitaxel and ascorbate Administered after before gemcitabine and ascorbate~* given for 3 weeks out of the 4 week cycle~* standard dose reductions are used~* up to 2 cycles are administered before standard of care CT scan~* decision to continue therapy is based disease response to therapy as measured from the CT scan~* treatment continues until disease progression is identified
Study: NCT00783172

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Opioid Growth Factor (OGF)
Description: Initial treatment is 150ug/kg (based on body weight of the patient) in a volume of 50ml sterile saline, IV (in the vein) over 45 minutes; subsequent treatments at dose of 250ug/kg
Study: NCT02905578

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nab-paclitaxel
Description: Administered intravenously the same day as nab-paclitaxel and ascorbate Administered after before gemcitabine and ascorbate~* given for 3 weeks out of the 4 week cycle~* standard dose reductions are used~* up to 2 cycles are administered before standard of care CT scan~* decision to continue therapy is based disease response to therapy as measured from the CT scan~* treatment continues until disease progression is identified

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pharmacological ascorbate
Description: Administered intravenously the same day as nab-paclitaxel and gemcitabine Administered after nab-paclitaxel and gemcitabine~* given 3 times weekly~* given for 4 weeks out of the 4 week cycle~* no dose reductions are used~* up to 2 cycles are administered before standard of care CT scan~* decision to continue therapy is based disease response to therapy as measured from the CT scan~* treatment continues until disease progression is identified
Study: NCT01924156

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adenovirus-transfected DC + CIK
Description: adenovirus-transfected DC vaccine plus CIK cells
Study: NCT03957356

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HLBLS-200
Description: The amount of HLBLS-200 applied will be determined by the investigator based on the resection area.
Study: NCT02080156

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Study: NCT00865189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered at the fixed dose of 5 milligrams per kilogram (mg/kg) as an IV infusion over 30 to 90 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered at the fixed dose of 5 milligrams per kilogram (mg/kg) as an IV infusion over 30 to 90 minutes.
Study: NCT01406223

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine patches

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nicotine patches

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine patches

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine patches

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo varenicline

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo varenicline

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo bupropion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo bupropion
Study: NCT00865189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin will be administered at a dose of 85 milligrams per square meter (mg/m\^2) as a 2-hour IV infusion.
Study: NCT01406223

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo bupropion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo patch

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo patch

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo patch
Study: NCT03197571

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: avelumab
Description: Fully human anti-PD-L1 IgG1 lambda monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Recombinant human anti-vascular endothelial growth factor (VEGF) IgG1 monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: 5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: (SP-4-2)-diamminedichloroplatinum(II)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5Fluorouracil (5-FU)
Description: 5-fluoro-2,4 (1H,3H)-pyrimidinedione

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fulvestrant
Description: 7-alpha-\[9-(4,4,5,5,5-pentafluoropentylsulphinyl) nonyl\]estra-1,3,5-(10)- triene-3,17-beta-diol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin
Description: Calcium N-\[p-\[\[\[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl\]methyl\]amino\]benzoyl\]-L-glutamate (1:1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: 5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovaza
Description: Omega-3-acid ethyl esters

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: (SBRT)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALT-803
Description: recombinant human super agonist interleukin-15 (IL-15) complex \[also known as IL-15N72D:IL-15RαSu/IgG1 Fc complex\]

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-011
Description: adenovirus serotype-5 \[Ad5\] \[E1-, E2b-\]-carcinoembryonic antigen \[CEA\] vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-021
Description: Ad5 \[E1-, E2b-\]-human epidermal growth factor receptor 2 \[HER2\] vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-051
Description: Ad5 \[E1-, E2b-\]-Brachyury vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-061
Description: Ad5 \[E1-, E2b-\]-mucin 1 \[MUC1\] vaccine
Study: NCT00865189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic Acid
Description: Folinic acid will be administered at a dose of 200 mg/m\^2 as a 2-hour infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: 5-fluorouracil will be administered at a dose of 400 mg/m\^2 as an IV bolus, then at a dose of 600 mg/m\^2 as a continuous infusion for 22 hours in Phase 1, and will be administered at a dose of 225 mg/m\^2 as a 24-hour infusion, 5 days a week, for 5 weeks in Phase 2.
Study: NCT03197571

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI-4000
Description: RAS yeast vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI-6207
Description: CEA yeast vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI-6301
Description: Brachyury yeast vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: haNK
Description: NK-92 \[CD16.158V, ER IL-2\], Suspension for Intravenous \[IV\] Infusion (haNK™ for Infusion)
Study: NCT02709304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine gel
Description: Gel used for insertion of urinary catheter containing local anesthetic to determine if patients have less discomfort postoperatively when this is used

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: standard gel
Description: Standard gel that is used to insert a urinary catheter that does not contain local anesthetic
Study: NCT00873405

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Silastic® ring sleeve gastrectomy
Description: SRSG group: ligation of the vessels of the greater curvature of the body and fundus of stomach; resection of the fundus and part of the body of stomach using a linear stapler (80 mm, Tyco®) and a 32-Fr tube to calibrate the remaining stomach; placement of a 6.2 cm Silastic® ring around the stomach, 5.0 cm below the esophagogastric junction.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Silastic® ring sleeve gastrectomy
Description: SRSG group: ligation of the vessels of the greater curvature of the body and fundus of stomach; resection of the fundus and part of the body of stomach using a linear stapler (80 mm, Tyco®) and a 32-Fr tube to calibrate the remaining stomach; placement of a 6.2 cm Silastic® ring around the stomach, 5.0 cm below the esophagogastric junction.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Silastic® ring gastric bypass
Description: SRGB group: creation of a small, proximal gastric pouch using a linear stapler (80 mm, Tyco®) and a 32-Fr tube to calibrate the gastric pouch; creation of an intestinal loop of 150 cm and a biliopancreatic loop of 40 cm; placement of a 6.2 cm Silastic® ring around the stomach, 5.0 cm below the esophagogastric junction.
Study: NCT02396602

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: miPlan intervention
Description: miPlan mobile contraceptive counseling waiting room app intervention
Study: NCT05945017

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Infloran® -Berne, Switzerland- (Bifidobacterium bifidum NCDO 2203 and Lactobacillus acidophilus NCDO 1748
Study: NCT00678912

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartcare/PS
Description: computer-driven protocol that adjusts pressure support level in pressure support mode to patient respiratory status
Study: NCT04272645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib 200 MG
Description: 200 MG orally BID Days 1-21

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 MG in 20 ML Injection
Description: 1200 mg IV on Day 1 of 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 MG in 20 ML Injection
Description: 1200 mg IV on Day 1 of 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib 150 MG
Description: 150 MG orally BID Days 1-21

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib 150 MG
Description: 150 MG orally BID Days 1-21
Study: NCT02422784

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Rooibos Iced-Tea (Control)
Description: Participants will consume 240 mL of Rooibos iced-tea daily for 6 weeks. The iced-tea beverage will not contain any added sugar or artificial sweeteners. Beverages will be prepared fresh weekly and picked up by participants during their weekly study visits.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Rooibos Tea - Vitamin D3
Description: Participants will consume 240 mL of Rooibos iced-tea fortified with 1000 IU of water soluable Vitamin D3 daily for 6 weeks. The iced-tea beverage will not contain any added sugar or artificial sweeteners. Beverages will be prepared fresh weekly and picked up by participants during their weekly study visits.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Rooibos Tea- Vitamin D3 & Calcium
Description: Participants will consume 240 mL of Rooibos iced-tea fortified with 1000 IU of water soluable Vitamin D3 and 360 mg of Calicum daily for 6 weeks. The iced-tea beverage will not contain any added sugar or artificial sweeteners. Beverages will be prepared fresh weekly and picked up by participants during their weekly study visits.
Study: NCT01595802

Intervention type: DEVICE
Intervention: Nautilus NeuroWave
Description: The Nautilus NeuroWave device will be utilized on subjects with sub-arachnoid hemorrhage that undergo TCD measurements to diagnose Vasospasm. A recording will be obtained using the device each time a TCD measurement is made.~In this intervention, patients are recorded using the Nautilus Neurowave device.

Intervention type: DEVICE
Intervention: Nautilus NeuroWave
Description: The Nautilus NeuroWave device will be utilized on subjects with sub-arachnoid hemorrhage that undergo TCD measurements to diagnose Vasospasm. A recording will be obtained using the device each time a TCD measurement is made.~In this intervention, patients are recorded using the Nautilus Neurowave device.

Intervention type: DEVICE
Intervention: Transcranial Doppler (TCD)
Description: Subjects with sub-arachnoid hemorrhage undergo TCD measurements to diagnose Vasospasm. Patients that were detected to have a vasospasm using TCD will also be classified as having mild, moderate and severe vasospasm.

Intervention type: DEVICE
Intervention: Transcranial Doppler (TCD)
Description: Subjects with sub-arachnoid hemorrhage undergo TCD measurements to diagnose Vasospasm. Patients that were detected to have a vasospasm using TCD will also be classified as having mild, moderate and severe vasospasm.
Study: NCT03701386

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cesarean hysterectomy
Description: Elective cesarean hysterectomy will be planned at 37-38 weeks of gestation. An adequate amount of blood products was prepared to be available for transfusion. Delivery will be performed by the same multidisciplinary team, including two expert obstetricians, an assistant, an expert anesthesiologist, and a pediatrician.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: N&H sandwich technique
Description: In the N\&H group, after acceptable control of bleeding from the placental bed, the internal os of the cervix was identified a double uterine compression suture at the lower uterine segment with inflated Foley's catheter balloon tamponade will be performed
Study: NCT03796936

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motion-assisted, Multi-modular Memory Desensitization and Reconsolidation (3MDR) Therapy
Description: a novel treatment for PTSD combining aspects of virtual reality exposure therapy (VRET) and Eye Movement Desensitization and Reprocessing (EMDR), within the Computer Assisted Rehabilitation Environment (CAREN)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motion-assisted, Multi-modular Memory Desensitization and Reconsolidation (3MDR) Therapy
Description: a novel treatment for PTSD combining aspects of virtual reality exposure therapy (VRET) and Eye Movement Desensitization and Reprocessing (EMDR), within the Computer Assisted Rehabilitation Environment (CAREN)
Study: NCT00721565

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Behavior Change
Description: attend 12 supervised exercise sessions, attend 6 group sessions with psychologist, attend 3 counseling sessions with exercise specialist
Study: NCT02755116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: 10mg of olanzapine by mouth prior to anesthetic induction

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo by mouth prior to anesthetic induction
Study: NCT04478851

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Exercise Classes
Description: The exercise program to be implemented for rural cancer survivors will combine aerobic, resistance, balance, and flexibility exercises delivered in a circuit-type class setting or group personal training format, twice weekly for a 12-week period. If public health restrictions require closure of fitness facilities due to COVID-19, the program will be delivered online. If facilities are open, the sessions will be integrated in the community, delivered in-person. Whether delivered in-class or remotely, the program follows exercise progression principles (ie, frequency, intensity, time, type, overload and progression) over the 12-weeks, with tailoring of any exercise to meet individual participant needs as required, in order to promote fitness and wellness benefits. The exercise intervention is based on the Alberta Cancer Exercise (ACE) program.
Study: NCT04046536

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Description: A non-invasive treatment that emits magnetic pulses to stimulate the brain.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Description: A non-invasive treatment that emits magnetic pulses to stimulate the brain.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Magnetic Stimulation
Description: Sham rTMS will consist of the same parameters as active, however, the subject will not receive the actual magnetic stimulation due to the use of a double sided Active/Sham coil used specifically for research studies.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Magnetic Stimulation
Description: Sham rTMS will consist of the same parameters as active, however, the subject will not receive the actual magnetic stimulation due to the use of a double sided Active/Sham coil used specifically for research studies.